Itaconix (ITX) H2 2025 earnings summary

Executive summary

• Achieved record revenues of GBP 10.5 million (or $10.5m) and gross profits of GBP 3.6 million (or $3.6m), both up 61% year-over-year, maintaining a 35% gross margin.

• Adjusted EBITDA loss reduced to GBP 600,000 (or $0.6m) from GBP 1.8 million (or $1.8m) in 2024, reflecting operational progress and targeting breakeven in 2026.

• Strong cash position at year-end, with GBP 4.4 million (or $4.4m) in net cash and investments, supporting growth initiatives.

• Expanded customer base and product applications, with over 200 consumer products using six ingredient classes, and growth driven by EMEA and North American markets.

Financial highlights

• Revenue grew 61% year-over-year to GBP 10.5 million (or $10.5m), with three consecutive halves of revenue growth.

• Gross profit reached GBP 3.6 million (or $3.6m), up GBP 1.4 million from 2024, with a gross margin of 35%.

• Adjusted EBITDA loss narrowed to GBP 600,000 (or $0.6m) from GBP 1.8 million (or $1.8m) in 2024.

• Performance Ingredients segment revenue rose 60% to GBP 7.6 million (or $7.6m), with a 41% average gross margin; SPARX Formulated Solutions revenue grew 65% to GBP 2.9 million (or $2.9m), with gross margins of 10–20%.

• Net cash and investments at GBP 4.4 million (or $4.4m), down from GBP 6.7 million (or $6.7m) at prior year-end due to working capital and capex.

Outlook and guidance

• Management expects continued revenue growth in line with consensus (GBP 13.3 million or $13.3m for 2026) and positive adjusted EBITDA (GBP 300,000 or $0.3m), with cash & equivalents of GBP 3.2 million (or $3.2m).

• Targeting GBP 25–30 million in revenue within five years, focusing on EMEA detergent accounts and North American dish detergent volumes.

• Anticipates EBITDA profitability in H2 2026, with positive adjusted EBITDA for the full year.

• Plans to reduce working capital days and maintain strong cash reserves.

• Focus on increasing unit dose detergent market share, expanding scale inhibition in EMEA and North America, and advancing BIO*Asterix consumer products.